Korea's Celltrion To Supply Biosimilars To Europe And Japan This Year, Boosting Forecast

SEOUL - South Korea's biosimilar front-runner Celltrion said it would provide biosimilar products of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Europe and Japan this year worth KRW 293 billion ($263.61 million)